EP1276468A1 - Utilisation de vecteurs particulaires dans l' immunomodulation - Google Patents
Utilisation de vecteurs particulaires dans l' immunomodulationInfo
- Publication number
- EP1276468A1 EP1276468A1 EP01931773A EP01931773A EP1276468A1 EP 1276468 A1 EP1276468 A1 EP 1276468A1 EP 01931773 A EP01931773 A EP 01931773A EP 01931773 A EP01931773 A EP 01931773A EP 1276468 A1 EP1276468 A1 EP 1276468A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substance
- antigen
- vector
- use according
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 9
- 239000013598 vector Substances 0.000 title claims description 67
- 239000000203 mixture Substances 0.000 claims abstract description 128
- 108091007433 antigens Proteins 0.000 claims abstract description 70
- 102000036639 antigens Human genes 0.000 claims abstract description 70
- 239000000427 antigen Substances 0.000 claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 55
- 239000000126 substance Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 42
- 230000028993 immune response Effects 0.000 claims abstract description 35
- 239000003446 ligand Substances 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000003612 virological effect Effects 0.000 claims abstract description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 93
- 108010002350 Interleukin-2 Proteins 0.000 claims description 93
- 239000002671 adjuvant Substances 0.000 claims description 62
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 39
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 24
- 235000012000 cholesterol Nutrition 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 102000004127 Cytokines Human genes 0.000 claims description 21
- 108090000695 Cytokines Proteins 0.000 claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- 210000000987 immune system Anatomy 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 230000003993 interaction Effects 0.000 claims description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 13
- 229920001542 oligosaccharide Polymers 0.000 claims description 13
- 150000002482 oligosaccharides Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 102000019034 Chemokines Human genes 0.000 claims description 10
- 108010012236 Chemokines Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 9
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 9
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- 102000015696 Interleukins Human genes 0.000 claims description 8
- 108010063738 Interleukins Proteins 0.000 claims description 8
- 239000000147 enterotoxin Substances 0.000 claims description 8
- 231100000655 enterotoxin Toxicity 0.000 claims description 8
- 229940047124 interferons Drugs 0.000 claims description 8
- 229940047122 interleukins Drugs 0.000 claims description 8
- 229930182490 saponin Natural products 0.000 claims description 8
- 150000007949 saponins Chemical class 0.000 claims description 8
- 235000017709 saponins Nutrition 0.000 claims description 8
- MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 7
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 7
- 102000034655 MIF Human genes 0.000 claims description 7
- 108060004872 MIF Proteins 0.000 claims description 7
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 150000003863 ammonium salts Chemical class 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 5
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 5
- 239000002245 particle Substances 0.000 abstract description 8
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 68
- 241000699670 Mus sp. Species 0.000 description 46
- 230000000694 effects Effects 0.000 description 28
- 206010022000 influenza Diseases 0.000 description 25
- 230000004044 response Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 239000010410 layer Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 101710154606 Hemagglutinin Proteins 0.000 description 17
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 17
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 17
- 101710176177 Protein A56 Proteins 0.000 description 17
- 239000000185 hemagglutinin Substances 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 125000002091 cationic group Chemical group 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- -1 lipid compounds Chemical class 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 125000003010 ionic group Chemical group 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 241001227713 Chiron Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101710110377 Immediate early protein IE1 Proteins 0.000 description 1
- 101710205424 Immediate-early protein 1 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000699667 Mus spretus Species 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- PUVAFTRIIUSGLK-UHFFFAOYSA-M trimethyl(oxiran-2-ylmethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1CO1 PUVAFTRIIUSGLK-UHFFFAOYSA-M 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the subject of the present invention is a process for improving the immunomodulatory properties of a substance, other than an antigen, capable of modulating the immunological response consisting in mixing said substance with hydrophilic particles carrying or not carrying ionic ligands and optionally covered with a layer of amphiphilic compounds.
- the invention relates to the treatment and / or prevention of diseases comprising an immunogenic character such as cancers or infections.
- the invention relates very particularly to a therapeutic composition, in particular a vaccine composition, and to their method of preparation.
- the invention particularly relates to the use of particulate vectors incorporating interleukin 2 for the preparation of medicaments intended for the treatment of cancers.
- Cancer is a disease characterized by an uncontrolled proliferation of certain cells, which escape the surveillance of the immune system.
- the role of the immune system is not only to reject pathogenic foreign bodies (viruses, bacteria, parasites ...) which can enter the human body, but also to eliminate cells with abnormal characteristics.
- Cancer cells may sometimes escape the vigilance of the immune system, for example by decreasing the expression of certain tumor-specific antigens, or of molecules involved in recognition by the immune system (proteins of the major histocompatibility complex ).
- the tumors are strongly immunogenic, the immune system cannot fight them, the lymphocytes being in an anergic state near the cancerous clusters.
- a new strategy developed in recent years consists in stimulating the immune system by injecting proteins of therapeutic interest, having a role in the regulation of the immune system.
- proteins of therapeutic interest having a role in the regulation of the immune system.
- proteins of therapeutic interest we can of course mention cytokines, but also other agents such as chemokines.
- cytokines we can focus on interleukins, interferons, TNF (tumor necrotizing factors), TGF (transforming growth factors), hematopoietic growth factors such as M-CSF and GM-CSF, but also factors that attract immune cells, such as MIF or RAMTES.
- IL-2 interleukin 2
- Thl type 1 helper T lymphocytes
- B T lymphocytes, natural killer cells NK
- IL-2 has anti-tumor properties, in that it can induce a regression of different solid tumors, of melanomas, of leukemias or of lymphomas, etc.
- IL-2 in chemotherapy faces many problems. To achieve the desired effect, it is often necessary to administer large doses of protein, which can cause annoying side effects (fever, erythema, edema). Furthermore, the purification of this protein is difficult, it is generally produced by genetic engineering, and is therefore expensive. In addition, cytokines are often unstable in solution, even at 4 ° C, which poses a conservation problem. In addition, the processes for preparing the solutions comprising IL-2 contain a step of adding stabilizing protein, often albumin, which becomes difficult to accept for regulatory agencies, due to the risks posed by the use of albumin.
- stabilizing protein often albumin
- the present invention proposes to solve these various problems, by implementing a new way of formulating the compositions containing IL-2, which makes it possible to obtain solutions having an activity, in particular anti-tumor activity, greater than the usual formulations.
- This new formulation also increases the stability of IL-2.
- the invention can be used for the manufacture of a medicament which can be administered intranasally or orally, an active principle delivery system having a very significant improvement over the systems previously described.
- a formulation according to the invention makes it possible to dispense with the presence of albumin in the compositions comprising IL-2, intended for administration in injectable form.
- BVSM also referred to below as "BVSM”.
- BVSM A first type of BVSM, and its preparation process, have been described in European patent No. 344 040. These are particles comprising from the inside to the outside: a non-liquid hydrophilic central core consisting of a matrix of naturally or chemically crosslinked polysaccharides or oligosaccharides which can be modified by various ionic groups; - a layer of fatty acids grafted by covalent bonds to the nucleus; one or more lipid layers consisting in particular of phospholipids.
- Patent applications published under the numbers WO 94/20078, WO 96/06638 and EP 782 851 describe these BVSMs, their manufacture, their association with various active ingredients and their use for the preparation of pharmaceutical compositions.
- the hydrophilic nucleus can be obtained by various methods already described previously (thus the patents EP344040, WO92 / 21329, WO94 / 20078), and the crosslinking methods are known to those skilled in the art, the polysaccharide can be positively charged or negatively, by the grafting of ionic, cationic or anionic groups, to the sugars composing the polymer. These groups can be chosen from quaternary ammonium or carboxymethyl functions. The methods have been described in WO92 / 21329 and the patents cited above.
- the charge of the polysaccharide core of the vectors of the compositions according to the invention is generally preferably a positive charge.
- the vectors whose hearts contain negative charges may sometimes be preferred, in particular in a composition for use in injectable form.
- the aforementioned patents also describe the protocols that a person skilled in the art can use for the incorporation of the external lipid layer. It is preferably composed of "DPPC-like", that is to say of DPPC (dipalmitoyl phosphatidyl choline) or any other compound having the same properties as this product, in which cholesterol is added.
- Other lipid compounds can be used in particular phospholipids or ceramides, to which other constituents, for example constituents of biological membranes, can be added.
- the DPPC / Cholesterol mass ratio is 70/30.
- BVSMs are formed from a crosslinked hydrophilic polymer, preferably polysaccharides, in the form of nanoparticulate gel, these BVSMs are said to be of PSC type (or NPS in French). As indicated above, this polymer can optionally carry positive ionic ligands, BVSM said cationic, or negative, BVSM said anionic. This charged or uncharged polymer is optionally covered with a layer of amphiphilic compounds, preferably phospholipids, BVSM called Light type described in PCT patent application WO94 / 20078.
- the size of the BVSM is between 20 and 200 nm, preferably between 50 and 100 nm and more preferably between 60 and 80 nm.
- the BVSMs can be sterilized by filtration and their association with the active ingredients is made on fully manufactured BVSMs (Major et al., Biochem. & Biophys. Acta (1997), 1327, 32-40). This allows biological molecules, which are particularly fragile, to be worked under optimal conditions.
- BVSM protects biological molecules from degradation (Prieur R. et al. Vaccines (1996) Vol 14, N ° 6 pp. 511-520 Combination of hCMV recombinant IE1 protein with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4).
- BVSM are known to be used as transporters of active substances, for example peptides, antigens or oligonucleotides.
- active substances for example peptides, antigens or oligonucleotides.
- the active substance such as ionic interactions between the cationic nucleus of the BVSM and the anionic oligonucleotide.
- the oligonucleotide / BVSM ratio is 5 to 10% and the measured association yield is greater than 90%.
- BVSM allow to improve the immunomodulatory properties of a substance other than an antigen capable of modulating the immunological response.
- substances are more particularly:
- - adjuvants capable of amplifying, regulating or modifying the immune response, - cytokines and chemokines whose intrinsic property is to modify the activity of cells of the immune system, immunosuppressants due to their use in the treatment of allergies , and / or rejection of the transplant,
- lymphocyte cells in particular B cells and T lymphocytes.
- the latter can be classified into two subtypes based on their expression of surface antigens CD4 and CD8.
- CD4 + cells are generally involved in "helper” functions. In particular, they secrete cytokines which induce the proliferation and maturation of other lymphocyte cells.
- helper T lymphocytes Two profiles of helper T lymphocytes can be defined:
- Thl profile which characterizes a cell-mediated response, with the induction of cytokines in particular of IL2, IL7 and gamma interferon, the stimulation of CTLs and the induction of antibodies type IgG2a, and
- Th2 profile which characterizes a humoral mediation response, with the induction of cytokines including IL4, IL5 and IL10, and the presence of antibodies of the IgGl and IgE type.
- Protein antigens the presentation of which by antigen presenting cells (APC) is mainly done by MHC class II, induce a Th2-oriented response.
- APC antigen presenting cells
- the DNA which allows, after transfection, to present the antigens directly on MHC class I, orients the immune response towards Thl.
- Certain adjuvants are known to orient the response mainly towards Thl or Th2.
- the aluminum salts which induce an IgG1-type serum response are considered to be Th2.
- adjuvants such as lipid A derivatives (MPL) or QuilA derivatives, which induce an IgG2a and CTL response, are considered to be Thl. It would therefore be useful to have means allowing to act on the Thl / Th2 balance, which is precisely what the present invention proposes to achieve.
- the BVSM does not act as an adjuvant, because only it does not induce activation of the immune system, but as a "carrier" allowing better penetration and / or better presentation of the antigen to the presenting cells.
- the results obtained showed the contribution of BVSM on the adjuvant power of BTC, MPL and ODN.
- the adjuvant power is visualized in a different way:
- the invention therefore firstly relates to the use of a vector of the type comprising a non-liquid hydrophilic nucleus for the preparation of a medicament intended for the treatment of cancers and / or viral diseases, said vector being associated in the drug with at least one substance, other than an antigen, capable of modulating the immune response.
- the vector is advantageously of the type comprising a non-liquid hydrophilic nucleus and an external layer constituted at least in part of amphiphilic compounds, associated with the nucleus by hydrophobic interactions and / or ionic bonds.
- the outer layer consists of dipalmitoyl phosphatidyl choline (DDPC) and cholesterol.
- DDPC dipalmitoyl phosphatidyl choline
- the non-liquid hydrophilic nucleus consists of a matrix of naturally or chemically crosslinked polysaccharides or oligosaccharides, onto which ionic ligands are grafted.
- the ionic ligands are preferably positively charged, like quaternary ammoniums.
- Particulate vectors having a non-liquid hydrophilic core and an external layer made up of amphiphilic compounds have already been described, in particular in patent application WO94 / 20078.
- the hydrophilic nucleus can be obtained by various methods already described above (thus the patents EP344040, WO92 / 21329, WO94 / 20078), and the crosslinking methods are known to those skilled in the art, the polysaccharide can be positively or negatively charged, by the grafting of ionic, cationic or anionic groups, to the sugars composing the polymer. These groups can be chosen from quaternary ammonium or carboxymethyl functions.
- the methods have been described in WO92 / 21329 and the patents cited above.
- the charge of the polysaccharide core of the vectors of the compositions according to the invention is generally preferably a positive charge. However, vectors whose hearts contain negative charges can sometimes be preferred, in particular in a composition for use in injectable form.
- the aforementioned patents also describe the protocols that a person skilled in the art can use for the incorporation of the external lipid layer.
- This is preferably composed of "DPPC-like", that is to say of DPPC (dipalmitoyl phosphatidyl choline) or any other compound having the same properties as this product, in which cholesterol is added.
- DPPC-like that is to say of DPPC (dipalmitoyl phosphatidyl choline) or any other compound having the same properties as this product, in which cholesterol is added.
- other lipid compounds can be used in particular phospholipids or ceramides, to which other constituents can be added, for example constituents of biological membranes.
- the DPPC / Cholesterol mass ratio is 70/30.
- the substance / particle weight ratio is between approximately 1% and 20%, preferably between approximately 5% and 10%.
- the weight ratio (substance) / (core + outer layer) is 1 to 10.
- a first class of substances, other than an antigen, capable of modulating the immune response includes proteins of therapeutic interest which play a role in the functioning of the immune system. It is more particularly a cytokine or a chemokine, preferably chosen from the group comprising interleukins, interferons, TNF, TGF, G-CSF, GM-CSF, MIF, RANTES , or a mixture of these.
- adjuvant is meant a molecule making it possible to amplify, regulate or orient the specific immune response of an antigen.
- various molecules belonging to the main categories of adjuvants have been tested in the context of the present invention, such as bacterial products (endotoxins, wall components), cytokines, oligonucleotides (CpG).
- bacterial products endotoxins, wall components
- cytokines oligonucleotides
- - bacterial enterotoxins such as CT, CTB, LT,
- the substance, other than an antigen, capable of modulating the immune response is preferably chosen from: adjuvants, capable of amplifying, regulating or modifying the immune response, cytokines and chemokines whose intrinsic property is to modify the activity of cells of the immune system, immunosuppressants due to their use in the treatment of allergies and / or transplant rejection, - substances capable of modifying the balance
- the invention envisages more particularly as a substance, the immunomodulatory properties of which it is desired to improve, cytokines which stimulate the activity of immune cells, and among these, IL2, IL11 and GM- CSF. Indeed, cytokines stimulate or inhibit the activity of immune cells.
- a very preferred embodiment of the invention relates to the use of a vector comprising: a) a non-liquid hydrophilic core, consisting of a matrix of polysaccharides or of oligosaccharides naturally or chemically crosslinked, onto which ionic ligands are grafted, b) an external layer constituted at least in part of amphiphilic compounds, associated with the nucleus by hydrophobic interactions and / or ionic bonds and c) incorporating interleukin 2 for the preparation of a medicament intended for the treatment of cancers.
- Such a pharmaceutical composition containing a vector comprising: a) a non-liquid hydrophilic nucleus, consisting of a matrix of naturally or chemically cross-linked polysaccharides or oligosaccharides, onto which ionic ligands are grafted, b) an outer layer consisting at least partly of amphiphilic compounds, associated with the nucleus by hydrophobic interactions and / or ionic bonds and c) incorporating interleukin 2 also forms part of the invention.
- a vector comprising: a) a non-liquid hydrophilic nucleus, consisting of a matrix of naturally or chemically cross-linked polysaccharides or oligosaccharides, onto which ionic ligands are grafted, b) an outer layer consisting at least partly of amphiphilic compounds, associated with the nucleus by hydrophobic interactions and / or ionic bonds and c) incorporating interleukin 2 also forms part of the invention.
- the invention relates to the treatment of cancers of the non-immunogenic or weakly immunogenic type, and / or to the treatment of infections, in particular viral infections such as AIDS or chronic hepatitis where the immunomodulators have been proposed in addition to therapeutic treatments. to activate the immune response.
- a composition for the implementation of this use comprises hydrophilic particles carrying or not ionic ligands and optionally covered with a layer of amphiphilic compounds in which are incorporated proteins of therapeutic interest or adjuvants as defined above. Such a composition does not include an antigen.
- the cancers which can be treated with a composition according to the invention can be of all kinds.
- cancers of the ENT sphere, the esophagus, the stomach, the colon, the rectum, the prostate, the liver, the pancreas, the breast, the cervix or the uterine body, the ovary, kidney, bladder, bone, or thyroid we also add bronchopulmonary cancers, malignant melanomas, brain tumors, lymphomas (Hodgskinian or not), leukemias (myeloids or lymphoids), cancers of unknown primary location. These cancers can be primary or metastatic.
- compositions according to the invention can be immunogenic or not.
- the Applicant has shown that the compositions according to the invention are particularly effective in the treatment and control of cancers with little or no immunogenicity.
- compositions and medicaments according to the invention can be administered in various ways, in particular parenterally.
- the compositions according to the invention can thus be administered intravenously, subcutaneously, intramuscularly, or intradermally. Administration can also be carried out (and this is a big advantage of the invention) orally or intranasally.
- the compositions allowing an oral intake can be tablets, capsules, powders, granules or oral suspensions or solutions. They also include forms of sublingual and oral administration. It is optionally possible to add certain excipients to the pharmaceutical compositions according to the invention. It is thus possible to use any kind of binding, surfactant, coating, dispersion or wetting agents.
- the Applicant has shown that these vectors are capable of fixing IL-2 very efficiently, that the protein retains its biological activity, and that, unexpectedly, this activity is increased compared to the unformulated protein.
- the Applicant has also shown that a formulation according to the invention makes it possible to stabilize the protein in solution, in the same way as in the presence of albumin.
- a vector comprising: (a) a non-liquid hydrophilic nucleus consisting of a polysaccharide matrix or of naturally or chemically crosslinked oligosaccharides, onto which ionic ligands of positive or negative charge are grafted, (b) an external layer constituted at least in part of amphiphilic compounds associated with the nucleus by hydrophobic interactions and / or ionic bonds and (c) incorporating IL-2 for the preparation of a medicament intended for the administration in injectable form of said IL-2 protein in the absence of albumin is also part of the invention.
- the Applicant has shown that the vector-protein association remains stable (measured by a maintenance of the activity after several months of storage), which presents an improvement compared to the previous technique, in which the therapeutic preparations d 'IL-2 cannot be stored, which further increases the cost.
- the Applicant has shown that, surprisingly, the IL-2 formulated according to the invention, and administered by the intranasal route has an activity similar or superior to IL-2 administered by more conventional routes, such as subcutaneously. The use of a vector according to the invention therefore makes it possible to get rid of all the various problems previously posed when using IL-2.
- a vector according to the invention can therefore be used for the treatment of cancers where a potentiation of the immune response is sought.
- a subject of the invention is also a method for improving the immunomodulatory properties of a substance, other than an antigen, capable of modulating the immune response, characterized in that it comprises the mixing of said substance with vectors of the type comprising a non-liquid hydrophilic nucleus.
- the vectors are of the type comprising a non-liquid hydrophilic core and an external layer made up at least in part of compounds amphiphilic, associated with the nucleus by hydrophobic interactions and / or ionic bonds.
- the non-liquid hydrophilic nucleus consists of a matrix of naturally or chemically crosslinked polysaccharides or oligosaccharides, onto which ionic ligands, in particular of positive charge, are grafted, such as quaternary ammoniums.
- the outer layer is for example formed of dipalmitoyl phosphatidyl choline (DDPC) and cholesterol, in particular according to the mass ratio DPPC / cholesterol is 70/30.
- DDPC dipalmitoyl phosphatidyl choline
- DPPC / cholesterol is 70/30.
- the weight ratio substance / vectors in the mixture is between approximately 1% and 20%, preferably between approximately 5% and 10%.
- the substance, other than an antigen, capable of modulating the immune response is chosen from:
- a protein of therapeutic interest which plays a role in the functioning of the immune system, such as a cytokine or a chemokine, preferably chosen from the group comprising interleukins, interferons, TNF, TGF, G-CSF, GM-CSF, MIF, RANTES, or a mixture of these,
- an adjuvant in particular chosen from the group comprising bacterial enterotoxins, liposaccharide derivatives, oligonucleotides, saponins, ammonium salts and their derivatives, DT or TT type proteins or a mixture thereof. a substance capable of modifying the Thl / Th2 balance. - an immunosuppressant.
- the invention also relates to a pharmaceutical composition, characterized in that it comprises: a vector of the type comprising a non-liquid hydrophilic nucleus consisting of a matrix of naturally or chemically crosslinked polysaccharides or oligosaccharides, onto which are grafted ionic ligands, and an outer layer consisting at least of part of amphiphilic compounds, associated with the nucleus by hydrophobic interactions and / or ionic bonds, and
- the vector, the protein of therapeutic interest and the adjuvant being defined as above.
- the invention also relates very particularly to the use of vectors, as defined above, for the preparation of a therapeutic or prophylactic vaccine composition, said particles being mixed in the composition with at least one antigen and at least one substance capable of modulating the immunological response to said antigen.
- the invention is particularly interested in the treatment and / or prevention of viral diseases, in particular AIDS and chronic hepatitis, but also cancers having an immunogenic character.
- the invention therefore relates very specifically to a vaccine composition characterized in that it comprises vectors as defined above and an antigen or a mixture of antigens, and at least one substance capable of modulating the immunological response to said antigen.
- the substance capable of modulating the immunological response to the antigen present in the composition of the invention is preferably an adjuvant.
- the invention contemplates bacterial products (endotoxins, wall components), cytokines, oligonucleotides (CpG).
- bacterial products endotoxins, wall components
- cytokines cytokines
- oligonucleotides CpG
- - bacterial enterotoxins such as CT, CTB,
- the substance / particle weight ratio is between approximately 1% and 20%, preferably between approximately 5% and 10%.
- the invention is very particularly suitable for the preparation of a composition, more particularly for mucosal administration, in particular nasal administration, but any other mode of administration, for example parenteral, can be envisaged.
- Example 1 the preparation and the biological activity of BVSM-IL2.
- Example 2 (ii) the effect in mice of
- BVSM on the immunogenicity of a trivalent split Influenza to that of different adjuvants, and (iii) the effect in mice of the co-administration of the formulation and of various adjuvants on the immunogenicity of a trivalent split Influenza.
- Figure 1 ELISA analysis of BVSM-IL2 interactions, in particular to calculate the optimal mass ratio between the protein of interest and the vector. Values are given in Arbitrary Units (AU).
- AU Arbitrary Units
- Figure 2 Analysis of BVSM-IL2 on a Biacore device. Comparison of the refraction between a free IL-2 composition and the BVSM-IL2 composition. Values are given in Units of Refraction (UK).
- Figure 3 Proliferation of stimulated peripheral mononuclear cells previously stimulated by PHA, and by BVSM-IL2 of various compositions. The proliferation is measured by incorporation of H-labeled thymidine and is proportional to the number of counts per minute (cpm) noted.
- Figure 4 Effect of different IL-2 formulations on the implantation and growth of a tumor in a TS / A model, after co-administration.
- the symbols represent: PBS, saline buffer; IL-2, unformulated interleukin 2; KY, cationic core vector and DPPC / Cholesterol layer; KY / IL-2, KY vector formulated with IL-2.
- Figure 5 Effect of different IL-2 formulations on the implantation and growth of a tumor in a TS / A model, after administration into the contralateral flank of BALB / c mice.
- the symbols are the same as before, the numerical values indicated correspond to the UI values of IL-2.
- FIG. 6 A. Rejection properties of a TS / A tumor implanted by subcutaneous administration of KY / IL-2 in the contralateral flank of BALB / c mice at one or five site (s), six days after implantation. The symbols are the same as before, the numerical values indicated correspond to the UI values of IL-2.
- B protection of cured mice after re-injection of TS / A tumor cells. In the two figures, the number of mice presenting tumors is indicated in brackets.
- Figure 7 A. Rejection properties of a tumor
- the symbols are the same as before, the numerical values indicated correspond to the UI values of IL-2.
- Figure 8 CTL anti-tumor activity in mice having rejected TS / A cells after administration of KY / IL-2.
- Figure 9 Biacore analysis (surface plasmon resonance) of the association of CTB with BVSM TM as a function of CTB concentration.
- Figure 10 Biacore analysis of the association of MPL with BVSM TM as a function of the MPL concentration.
- Figure 11 inhibition of the association of Harbin split B on BVSM in the presence of an increasing amount of CTB.
- Figure 12 inhibition of the Harbin split B association on BVSM in the presence of an increasing amount of MPL.
- Figure 13 sensorgrams obtained by comparing the two modes of preparation of BTC and influenza antigens on the BVSM immobilized on the HPA sensorship. First, the CTB then the antigen are deposited successively on the BVSM (curve A) and vice versa (curve B).
- Figure 14 sensorgrams obtained by comparing the two modes of preparation of MPL and influenza antigens on the BVSM immobilized on the HPA sensorship. First, the MPL and then the antigen are deposited successively on the BVSM (curve A) and vice versa (curve B).
- FIG. 15 specific titration of the B / Harbin split of the pools of sera (IgG) and of the nasal secretions (IgA) of mice administered by the trivalent formulations and the antigen controls associated or not with BTC.
- Figure 16 specific titration of the B / Harbin split of the pools of sera (IgG) and of the nasal secretions (IgA) of mice administered by the trivalent formulations and the antigen controls associated or not with MPL.
- FIG. 17 represents the specific titration of the B / Harbin split of the pools of sera (IgG) and of the nasal secretions (IgA) of mice administered by the trivalent formulations and the antigen controls associated or not with the oligonucleotides.
- Example 1 Preparation and biological activity of BVSM-IL2.
- vectors loaded with IL-2 The vectors used (BVSM) in this example have been described previously. These are cationic vectors having a lipid layer of DPPC-
- a composition according to the invention is obtained by the BVSM-IL2 bond by simple mixing of the two compounds, in a weight ratio of 10/1, and in a buffered saline solution (PBS).
- PBS buffered saline solution
- the optimal mass ratio of BVSM with respect to the protein is determined by ELISA analysis, according to a method well known to those skilled in the art.
- the wells are covered with an anti-IL2 antibody, and saturated with BSA (bovine serum albumin).
- BSA bovine serum albumin
- the preparation of IL-2 to be tested is added, then a second biotinylated anti-IL2 antibody is added.
- streptavidin linked to a peroxidase followed by the addition of a substrate of said peroxidase makes it possible to determine the amount of IL-2 present in the solution, by colorimetry.
- the values obtained are expressed in Arbitrary Units, a value being all the higher as there is IL-2 present in the solution tested.
- the preparations tested are preparations into which the same amount of IL-2 has been introduced, in the presence of vectors in various proportions, or in their absence, with or without BSA as a protein stabilizer.
- the rate of association of IL-2 with the vectors is determined by the surface resonance technique of the plasmon in a Biacore X device, following the manufacturer's instructions. This method allows the detection of differences in the refractive index of a surface layer of a solution in contact with the detection chip, by illumination with polarized monochromatic light.
- the operating protocol is as follows:
- the BVSM (0.05 g / l) are adsorbed on the surface of the detection chip;
- the free IL-2 is injected (1-6 mg / ml) in order to determine the standard curve (expressed as resonance units, RU) which is a function of the concentration of protein injected; - After regeneration, a preparation is injected as prepared in Example l.A, in which the BVSM-IL2 are present, as well as free IL-2. Only the latter can associate with the BVSMs fixed to the surface of the detection chip. This protocol makes it possible to determine the concentration of free IL-2 in the formulation of Example 1.A and to deduce therefrom the rate of association BVSM-IL2.
- This example shows the importance of the composition of the nuclei and layers of the vector on the biological activity of IL-2.
- IL-2 associated with the various BVSMs.
- the biological activity of IL-2 associated with the various BVSMs is evaluated by measuring the proliferation of blood mononuclear cells, calculated by incorporating H-labeled thymidine. These cells have previously been stimulated by compounds (PHA) which induce expression of the CD25 receptor, which has a strong affinity for IL-2.
- PHA compounds
- Preparations of IL-2 in solution are generally not stable in solution at 4 ° C, IL-2 losing its biological activity.
- the BVSM-IL2 preparation (QAE / DPPC / Chol) remains stable after two months of storage at 4 ° C., 95% of the biological activity of fresh IL-2 being maintained, as measured by incorporation of thymidine labeled with H in CTLL-2 murine cells.
- BVSM-IL2 The activity of BVSM-IL2 (KY / IL2, mass ratio 10/1) was tested in the TS / A tumor model (undifferentiated, non immunogenic breast adenocarcinoma), in a tumor implantation rejection model, or a model for the treatment of previously implanted tumors.
- A. Co-administration in the same flank 5.10 tumor cells are co-administered to female BALB / c mice subcutaneously (sc), as well as the BVSM-IL2 (KY / IL-2) corresponding to the IL-2 concentration indicated on Figure 4.
- the vectors are also administered alone or unformulated IL-2, or simple PBS. The implantation and the evolution of the size of the tumors are measured.
- FIG. 4 clearly shows that there is implantation of the tumor cells and tumor growth after administration of the vectors alone or of IL-2 alone, while the IL-2 formulated with the KY vectors makes it possible to retard growth. tumor.
- FIG. 5 shows that the contralateral administration of IL-2 complexed with the vectors allows the reduction of tumor growth, a result not observed with IL-2 not formulated, even used at a dose 100 times higher.
- Figure 6.B shows that the prior administration of KY / IL-2 partially protects the animals against a new challenge. In fact, four out of nine mice do not develop tumors, and tumor development is slowed down in other animals, compared to naive animals.
- the tumor is implanted and is palpable (surface of approximately 40 mm 2).
- the increase in tumor size is evaluated.
- Figure 7.A. shows that IL-2 complexed with vectors slows tumor growth, more significantly than IL-2 alone. The number of administrations does not seem to lead to differences in the results observed.
- mice 25.10 TS / A cells are reinjected into the ten mice described above, which no longer have tumors 48 days after administration of IL-2. Naive mice are used as controls.
- Figure 7.B shows that the prior administration of KY / IL-2 partially protects the animals against a new challenge. Indeed, four out of ten mice do not develop tumors, and tumor development is slowed down in other animals, compared to naive animals.
- the splenocytes are stimulated in vitro with TS / A cells for 6 days and the CTL activity against TS / A cells is studied.
- mice having received the KY / IL-2 by the subcutaneous route express a CTL activity specific for TS / A (FIG. 8.A), since the syngenic cells WEHI 164 or the YAC cells are not lysed.
- a specific CTL activity is also observed in the mice having received KY / IL-2 intranasally.
- Example 2 Effect of BVSM in Mice on the Immunogenicity of a Split Influenza Trivalent to That of Different Adjuvants, and Effect in Mice of Co-Administration of the Formulation and Different Adjuvants on the Immunogenicity of a Split Trivalent influenza.
- mice BALB / cJ / Rj female mice (10 weeks old at the start of the study) from the Janvier breeding center (Route des Chênes-Sec - BP5 - Le Genest-Saint-Isle), are acclimated for 7 days, 6 mice per cage before the start of the study.
- DPPC / Cholesterol corresponds to a polysaccharide core grafted with glycidyl trimethylammonium and surrounded by a layer of DPPC / Cholesterol. This type of vector is described in EP 687 173. b) Ad uvants.
- CTB cholera toxin subunit
- Trivalent Split Influenza A solution with 250 ⁇ g of HA / ml (83.3 ⁇ g / strain) of trivalent split Influenza is prepared with 3 split monovalent eggs from Biochem Pharma (Canada).
- HA hemagglutinin
- neuraminidase neuraminidase
- a formulation containing 250 ⁇ g of HA / ml (83.3 ⁇ g / strain) of trivalent split Influenza is prepared with the 3 monovalent split eggs above in order to obtain a HA / BVSM ratio equal to 1/89: 250 ⁇ g of trivalent HA /
- This formulation is obtained by mixing, at equal volume, 3 formulations with 250 ⁇ g of HA / 22.25 mg of BVSM / ml, each of the monovalent split.
- AS and AN prepared by mixing, at equal volume, 3 solutions with 250 ⁇ g of HA / ml of each of the monovalent split,
- the trivalent split solution is respectively prepared in phosphate buffered saline or in sterile water.
- subcutaneous 100 ⁇ l using a 1 ml syringe at the dorsal level for controls
- nasal 20 ⁇ l (10 ⁇ l / nostril) with a 10 ⁇ l micropipette for the samples tested and the controls
- the immunization includes two administrations, at OJ and D21 carried out in the same mode.
- - Blood sample - Blood sample.
- a blood sample of approximately 0.3 ml is taken from the retroorbital vein on D0 (control) and D35.
- the nasal cavities are washed using 500 ⁇ l of phosphate buffered saline - BSA 1% introduced into the trachea in the direction of the nasal turbines. The operation is thus repeated 3 times with the same PBS-BSA 1%.
- the nasal swab is stored in an Eppendorf tube at -20 ° C.
- the nasal secretions are collected on D35. b) Analysis of samples.
- the microplates (Nunc, Immunoplate maxisorb, polylabo) are coated with the influenza vaccine (100 ng HA / well in carbonate buffer, pH 9.6, 2 hrs at 37 ° C). After rinsing (three times in PBS-tween pH 7.6 buffer) then saturation with 250 ⁇ l / well of a 3% PBS-BSA solution (lhOO at 37 ° C), the ranges of serums or nasal secretions are incubated 1 hour to
- FIG. 9 shows the sensorgram obtained by association of the CTB and the BVSM immobilized on the HPA sensorchip as a function of the CTB concentration (1) 2.5 ⁇ g / ml; 2) 25 ⁇ g / ml; 3) 250 ⁇ g / ml in 45 mM PBS) (which corresponds to 0.3 X).
- Figure 10 shows the sensorgram obtained by association of MPL and BVSM immobilized on the sensorchip
- HPA as a function of the concentration of MPL (1) l, 56 ⁇ g / ml; 2) 3.125 ⁇ g / ml; 3) 6.25 ⁇ g / ml; 4) 12.5 ⁇ g / ml; 5) 25 ⁇ g / ml;
- BVSM / Adjuvant / split Influenza is then studied. Two methods are used:
- an adjuvant solution is introduced before adding the Influenza split.
- the Influenza split is introduced before adding the adjuvant.
- Figure 11 summarizes the results obtained in the case of a Harbin split B.
- Variable amounts of CTB are introduced on immobilized BVSM (1) No CTB, 2) 2.5Mg / ml, 3) 25 ⁇ g / ml, 4) 250 ⁇ g / ml in 45mM PBS).
- the Harbin monovalent split B at 25 ⁇ g / ml is then deposited on the adjuvant BVSM. There is clearly an inhibition of the association of the split on the BVSM when the CTB is added before the split.
- Figure 12 summarizes the results obtained in the case of MPL and a Harbin split B.
- Variable quantities of MPL are introduced into the immobilized BVSM (1) 1.56 ⁇ g / ml; 2) 3.12 ⁇ g / ml; 3) 6.25 ⁇ g / ml; 4) 12.5 ⁇ g / ml; 5) 25 ⁇ g / ml; 6) 50 ⁇ g / ml in 45 mM PBS).
- the 25 ⁇ g / ml split is then deposited on the adjuvant BVSM.
- BTC and in proportion to the amount of MPL, there is an inhibition of the association of the split on the BVSM when the adjuvant is added before the split.
- FIG. 13 represents the sensorgrams obtained by comparing the two modes of preparation in the case of BTC.
- the CTB is added to the immobilized BVSMs, then the monovalent split is introduced.
- the monovalent split is added to the immobilized BVSMs, then the CTB is introduced.
- FIG. 14 represents the sensorgrams obtained by comparing the two modes of preparation in the case of MPL.
- the BVSM makes it possible to associate an additional quantity of material corresponding to the MPL.
- BVSM / antigen the role of the BVSM as "Antigen Carrier" is preserved.
- a control is carried out under the same conditions but in the absence of BVSM TM resulting in a trivalent split at 250 ⁇ g of HA (83 ⁇ g / strain) / ml.
- a CTB solution is added to each of these preparations in order to obtain the corresponding adjuvant formulations and controls.
- mice 36 female BALB / cJ / Rj mice (10 weeks old at the start of the study) are divided into 6 groups at a rate of 6 mice per group. For each group, the treatment is carried out as described above. Table 1 below summarizes the treatment for each group.
- FIG. 15 summarizes the results obtained in specific titration of the B / Harbin split of the pools of sera (IgG) and of the nasal secretions (IgA) of mice. It allows the results of trivalent formulations containing CTB (F-CTB) to be compared with different controls. These controls are either antigen controls alone, or antigen controls associated with BTC, or the reference formulation (HA / BVSM ratio: 1/89). These results were confirmed by the analysis of the individual response against split B / Harbin and A / Nanchang.
- the reference formulation (FA) induces a level of type G antibody equivalent to the antigen control alone administered subcutaneously (AS) and a higher level of IgG than the control alone administered by the nasal route ( AN) (22, 4X).
- control antigens associated with CTB (ACTB) administered by the nasal route induce IgG markedly higher than the free antigen administered by the same route (increase of 22, 4X).
- these formulations (Ag + CTB) (ACTB) induce a strong mucosal immunity.
- FCTB CTB adjuvant
- ACTB reference control
- Protocol A trivalent formulation and the corresponding control are prepared at 250 ⁇ g of HA / ml (83.3 ⁇ g / strain) / of split Influenza.
- mice 36 female BALB / cJ / Rj mice (10 weeks old at the start of the study) are divided into 6 groups at a rate of 6 mice per group. For each group the treatment is carried out as described in the section "Materials and methods". Table 2 below summarizes the treatment of each group.
- FIG. 16 summarizes the results obtained in specific titration of the B / Harbin split of the pools of sera (IgG) and of the nasal secretions (IgA) of mice administered with the formulations adjuvanted by MPL. These results were confirmed by the analysis of the individual response against the split B / Harbin and A / Nanchang.
- the formulation combined with the MPL adjuvant induces a specific IgG response similar to the reference formulation. Conversely, for this adjuvant there is an effect
- a trivalent formulation and the corresponding control are prepared at 250 ⁇ g of HA / ml (83.3 ⁇ g / strain) / of split Influenza
- ODN oligonucleotide solution
- mice 42 female BALB / cJ / Rj mice (10 weeks old at the start of the study) are divided into 7 groups at a rate of 6 mice per group. For each group the treatment is carried out as described in the section "Materials and methods". Table 3 summarizes the treatment for each group.
- FIG. 17 summarizes the results obtained in specific titration of the B / Harbin split of the pools of sera (IgG) and of the nasal secretions (IgA) of mice administered with the formulations adjuvanted by the oligonucleotides. These results were confirmed by the analysis of the individual response against the split B / Harbin and A / Nanchang.
- the split influenza viruses associated with the BVSM or with the ODN administered by the nasal route induce a serum IgG response markedly higher than the free antigen administered by the same route (respective increase of 22, 4X and 7.3X). At the same time these formulations induce a strong mucosal immunity.
- the formulation associated with the ODN adjuvant induces an IgG response superior to the reference formulation and to its reference control (Ag + ODN).
- Ag + ODN the reference formulation
- the IgG titers obtained for the formulation being equal to the sum of the responses obtained for the antigen + ODN 1 (A ODN1 ) and for the
- a trivalent formulation and the corresponding control are prepared at 250 ⁇ g of HA / ml (83.3 ⁇ g / strain) / of split Influenza. From the trivalent formulation, three adjuvant formulations are obtained:
- BVSM TM / Ag / CTB By adding a CTB solution to the trivalent formulation. -TM
- BVSM / Ag / IL2 By adding to the trivalent formulation of a recombinant IL-2 solution
- mice 54 female BALB / cJ / Rj mice (10 weeks old at the start of the study) are divided into 9 groups at a rate of 6 mice per group. For each group, processing and sampling are carried out as described in the "Materials and methods" section.
- the analysis of the sera is carried out by ELISA test as described above, using either a murine anti IgG2a or a murine anti IgG1.
- Table 5 summarizes the results obtained in terms of the gamma globulin subtype (IgG2a and IgGl) of the various adjuvanted BVSM / influenza formulations and of the corresponding controls after nasal administration. Compared to the free antigen administered subcutaneously, the formulation
- BVSM / influenza administered via the nasal route induces a modest increase in specific IgG2a production.
- the addition of BTC to the Ag / BVSM TM formulation induces a marked increase in Ig2a production (multiplication by 5.4 of the Ig2a / Igl index versus Ag Sc). It is important to note that this modification of the Thl / Th2 balance is not predictable from the results obtained by the association of BTC with antigens. In fact, in this control group, there is a lowering of the Ig2a / lgGl index.
- MPL which when associated with split influenza promotes IgG2a production (index 47.6 versus 6.7 for Ag sc) only causes a minor change in the Thl / Th.2 balance after association with the Ag / BVSM TM formulation.
- the combination of adjuvant with the Antigen / BVSM formulations makes it possible to induce a qualitative modification of the immunological response.
- This association should allow, by a correct choice of the adjuvant used, to adapt the Thl / Th2 balance to the proposed vaccination strategy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0005295A FR2808193B1 (fr) | 2000-04-26 | 2000-04-26 | Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers |
FR0005295 | 2000-04-26 | ||
FR0005304 | 2000-04-26 | ||
FR0005304A FR2808194B1 (fr) | 2000-04-26 | 2000-04-26 | Utilisation de particules hydrophiles portant ou non des ligands ioniques pour ameliorer les proprietes immunomodulatrices d'une substance autre qu'un antigene, et les compositions pharmaceutiques ainsi obtenues |
PCT/FR2001/001289 WO2001080836A1 (fr) | 2000-04-26 | 2001-04-26 | Utilisation de vecteurs particulaires dans l'immunomodulation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1276468A1 true EP1276468A1 (fr) | 2003-01-22 |
Family
ID=26212366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01931773A Withdrawn EP1276468A1 (fr) | 2000-04-26 | 2001-04-26 | Utilisation de vecteurs particulaires dans l' immunomodulation |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040081686A1 (fr) |
EP (1) | EP1276468A1 (fr) |
JP (1) | JP2004508290A (fr) |
AU (1) | AU2001258476A1 (fr) |
CA (1) | CA2406949A1 (fr) |
WO (1) | WO2001080836A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
US20090047353A1 (en) * | 2005-11-04 | 2009-02-19 | Novartis Vaccines And Diagnostics Srl | Changing th1/th2 balance in split influenza vaccines with adjuvants |
PL2368572T3 (pl) | 2005-11-04 | 2020-11-16 | Seqirus UK Limited | Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej |
EP2044949A1 (fr) * | 2007-10-05 | 2009-04-08 | Immutep | Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes |
EP3173097A3 (fr) | 2009-02-10 | 2017-07-12 | Seqirus UK Limited | Vaccins contre la grippe dotés de quantités réduites de squalène |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2624741B1 (fr) * | 1987-12-21 | 1991-06-28 | Pasteur Institut | Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire |
FR2704145B1 (fr) * | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
NZ505876A (en) * | 1998-01-16 | 2002-12-20 | Univ Johns Hopkins | Solid nanosphere composition and delivery of a coacervate polymeric cation (gelatine or chitosan) and a polyanion (nucleic acids) |
-
2001
- 2001-04-26 WO PCT/FR2001/001289 patent/WO2001080836A1/fr not_active Application Discontinuation
- 2001-04-26 EP EP01931773A patent/EP1276468A1/fr not_active Withdrawn
- 2001-04-26 AU AU2001258476A patent/AU2001258476A1/en not_active Abandoned
- 2001-04-26 CA CA002406949A patent/CA2406949A1/fr not_active Abandoned
- 2001-04-26 JP JP2001577935A patent/JP2004508290A/ja active Pending
-
2002
- 2002-10-25 US US10/281,371 patent/US20040081686A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0180836A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2004508290A (ja) | 2004-03-18 |
AU2001258476A1 (en) | 2001-11-07 |
WO2001080836A1 (fr) | 2001-11-01 |
US20040081686A1 (en) | 2004-04-29 |
CA2406949A1 (fr) | 2001-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2296750C (fr) | Preparation d'un exosome et utilisation de cette vesicule cellulaire dans la stimulation d'une reponse immunitaire | |
EP1750707B1 (fr) | Composition immunostimulante comprenant au moins un agoniste du récepteur Toll-like 7 ou du récepteur Toll-like 8 et un agoniste du récepteur Toll-like 4 | |
EP1326636A2 (fr) | Composition vaccinale | |
WO1992022577A1 (fr) | Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant | |
CA2322712A1 (fr) | Methodes d'activation de cellules tueuses naturelles (nk) | |
FR3072880A1 (fr) | Formulation liposomale et son utilisation en therapie anti-tumorale | |
EP1651257B1 (fr) | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers | |
EP1276468A1 (fr) | Utilisation de vecteurs particulaires dans l' immunomodulation | |
EP1696954B1 (fr) | Composition vaccinale adjuvantée par une alkylphosphatidylcholine | |
CA2460779A1 (fr) | Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques | |
EP1024830B1 (fr) | Vecteurs d'antigenes sous forme de vesicules multilamellaires | |
FR2808194A1 (fr) | Utilisation de particules hydrophiles portant ou non des ligands ioniques pour ameliorer les proprietes immunomodulatrices d'une substance autre qu'un antigene, et les compositions pharmaceutiques ainsi obtenues | |
EP1948231B1 (fr) | Composition comprenant un vecteur synthétique colloidal biorésorbable et un vecteur viral | |
EP0748214B1 (fr) | Liposomes, et leur utilisation notamment pour l'obtention de compositions immunomodulatrices | |
EP0966532B1 (fr) | Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le contenant | |
FR2808193A1 (fr) | Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers | |
FR2775692A1 (fr) | Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre | |
EP1244690B1 (fr) | Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent | |
CN117731767A (zh) | 一种双抗原展示纳米疫苗及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021025 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TRIEBEL, FREDERIC Inventor name: BALLAND, OLIVIER Inventor name: EL MIR, SAMIR Inventor name: BETBEDER, DIDIER Inventor name: CASANOVA, ANNE Inventor name: MAJOR, MICHEL Inventor name: KRAVTZOFF, ROGER |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CEVA SANTE ANIMALE Owner name: INSTITUT GUSTAVE ROUSSY |
|
17Q | First examination report despatched |
Effective date: 20040130 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061031 |